GlaxoSmithKline is to pay $57 million (£35 million) for Genelabs, California-based specialists in infectious diseases, including hepatitis C. The companies …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

